Table 3.
Clinical and Demographic Variables of PD Patients with and without OH
| Variables | PD1 with OH2 (n=34) | PD without OH (n=50) | P value |
|---|---|---|---|
| Age (years) (mean±SD) | 71.3±8.8 | 74.2±7.1 | NS5 |
| PD duration (months) (mean±SD) | 82.7±60.7 | 38.5±46 | <0.01 |
| Gender (female/male) (%) | 58.8%/41.2% | 52%/48% | NS |
| Hypertension | 47.1% | 56% | NS |
| Anti-hypertensive medications (%) | 47.1% | 56% | NS |
| L-dopa3 (%) | 82.4% | 76% | NS |
| DA4 (%) | 29.4% | 20% | NS |
| Selegline (%) | 23.5% | 32% | NS |
| Amantadine (%) | 5.9% | 4% | NS |
1
Parkinson’s disease
2
Orthostatic hypotension
3
Levodopa
4
Dopamine agonists
5
Not significant